OBJECTIVE: A protective association between higher vitamin D levels and the onset of multiple sclerosis (MS) has been demonstrated; however, its role in modulating MS clinical course has been little studied. We investigated whether higher levels of serum 25-hydroxyvitamin D (25-OH-D) were associated with a lower risk of relapses in people with MS. METHODS: We conducted a prospective cohort study of 145 participants with relapsing-remitting MS from 2002 to 2005. Serum 25-OH-D levels were measured biannually, and the hazard of relapse was assessed using survival analysis. RESULTS: There was an inverse linear relationship between 25-OH-D levels and the hazard of relapse over the subsequent 6 months, with hazard ratio (HR) 0.91 (95% confidence interval [CI]: 0.85-0.97) per 10 nmol/l increase in 25-OH-D level (p = 0.006). When variation due to timing of blood collection was removed by estimating 25-OH-D at the start of each season, this association persisted, with HR 0.90 (95% CI, 0.83-0.98) per 10 nmol/l increase (p = 0.016). Taking into account the biological half-life of 25-OH-D, we estimated 25-OH-D at monthly intervals, resulting in a slightly enhanced association, with HR 0.88 (95% CI, 0.82-0.95) per 10 nmol/l increase (p = 0.001). Adjusting for potential confounders did not alter these findings. INTERPRETATION: In this prospective population-based cohort study, in a cohort largely on immunomodulatory therapy, higher 25-OH-D levels were associated with a reduced hazard of relapse. This occurred in a dose-dependent linear fashion, with each 10 nmol/l increase in 25-OH-D resulting in up to a 12% reduction in risk of relapse. Clinically, raising 25-OH-D levels by 50 nmol/l could halve the hazard of a relapse.
OBJECTIVE: A protective association between higher vitamin D levels and the onset of multiple sclerosis (MS) has been demonstrated; however, its role in modulating MS clinical course has been little studied. We investigated whether higher levels of serum 25-hydroxyvitamin D (25-OH-D) were associated with a lower risk of relapses in people with MS. METHODS: We conducted a prospective cohort study of 145 participants with relapsing-remitting MS from 2002 to 2005. Serum 25-OH-D levels were measured biannually, and the hazard of relapse was assessed using survival analysis. RESULTS: There was an inverse linear relationship between 25-OH-D levels and the hazard of relapse over the subsequent 6 months, with hazard ratio (HR) 0.91 (95% confidence interval [CI]: 0.85-0.97) per 10 nmol/l increase in 25-OH-D level (p = 0.006). When variation due to timing of blood collection was removed by estimating 25-OH-D at the start of each season, this association persisted, with HR 0.90 (95% CI, 0.83-0.98) per 10 nmol/l increase (p = 0.016). Taking into account the biological half-life of 25-OH-D, we estimated 25-OH-D at monthly intervals, resulting in a slightly enhanced association, with HR 0.88 (95% CI, 0.82-0.95) per 10 nmol/l increase (p = 0.001). Adjusting for potential confounders did not alter these findings. INTERPRETATION: In this prospective population-based cohort study, in a cohort largely on immunomodulatory therapy, higher 25-OH-D levels were associated with a reduced hazard of relapse. This occurred in a dose-dependent linear fashion, with each 10 nmol/l increase in 25-OH-D resulting in up to a 12% reduction in risk of relapse. Clinically, raising 25-OH-D levels by 50 nmol/l could halve the hazard of a relapse.
Authors: John F Payne; Robin Ray; David G Watson; Cecile Delille; Eva Rimler; Julia Cleveland; Michael J Lynn; Vin Tangpricha; Sunil K Srivastava Journal: Endocr Pract Date: 2012 Mar-Apr Impact factor: 3.443
Authors: Yanping Wang; Steven J Marling; Jinge G Zhu; Kyle S Severson; Hector F DeLuca Journal: Proc Natl Acad Sci U S A Date: 2012-05-16 Impact factor: 11.205
Authors: Muhammad Taimur Malik; Brian C Healy; Leslie A Benson; Pia Kivisakk; Alexander Musallam; Howard L Weiner; Tanuja Chitnis Journal: Neurology Date: 2014-05-21 Impact factor: 9.910
Authors: Manuel Zeitelhofer; Milena Z Adzemovic; David Gomez-Cabrero; Petra Bergman; Sonja Hochmeister; Marie N'diaye; Atul Paulson; Sabrina Ruhrmann; Malin Almgren; Jesper N Tegnér; Tomas J Ekström; André Ortlieb Guerreiro-Cacais; Maja Jagodic Journal: Proc Natl Acad Sci U S A Date: 2017-02-14 Impact factor: 11.205
Authors: Jennifer S Graves; Lisa F Barcellos; Steve Simpson; Anita Belman; Rui Lin; Bruce V Taylor; Anne-Louise Ponsonby; Terence Dwyer; Lauren Krupp; Emmanuelle Waubant; Ingrid A F van der Mei Journal: Mult Scler Relat Disord Date: 2017-10-14 Impact factor: 4.339
Authors: Laurie McLaughlin; Laura Clarke; Elham Khalilidehkordi; Helmut Butzkueven; Bruce Taylor; Simon A Broadley Journal: J Neurol Date: 2018-10-03 Impact factor: 4.849
Authors: Pavan Bhargava; Sonya U Steele; Emmanuelle Waubant; Nisha R Revirajan; Jacqueline Marcus; Marieme Dembele; Sandra D Cassard; Bruce W Hollis; Ciprian Crainiceanu; Ellen M Mowry Journal: Mult Scler Date: 2015-08-18 Impact factor: 6.312
Authors: Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson Journal: Mult Scler Date: 2013-04-23 Impact factor: 6.312